Gilead’s second-quarter Sovaldi sales increased from $2.3 billion during the first quarter of this year — the first full quarter of sales since the drug’s approval in December 2013. Analysts estimate Sovaldi will surpass $10 billion in sales this year, according to a report in The New York Times.
Since its approval, Sovaldi has been prescribed to more than 80,000 people in the U.S. and Europe, and the drug has a success rate of more than 90 percent. However, the Sovaldi’s high price tag has drawn criticism from many, including lawmakers.
The typical 12-week drug regimen of Sovaldi costs $84,000, but some patients require the drug for a longer period of time. Guidelines also suggest taking the drug along with others, adding to the overall care costs.
Earlier this month, Sens. Ron Wyden (D-Ore.), chairman of the Senate Finance Committee, and Chuck Grassley (R-Iowa), the Judiciary Committee’s ranking member, sent a letter seeking justification from Gilead for Sovaldi’s hefty price tag.
“Given the impact Sovaldi’s cost will have on Medicare, Medicaid and other federal spending, we need a better understanding of how your company arrived at the price for this drug,” the senators wrote in the letter.
More Articles on Sovaldi:
60% of Americans Are Worried They Won’t Be Able to Afford Specialty Drugs
Lawmakers Question Why Sovaldi Costs $1k a Pill
UnitedHealth Group Q1 Hepatitis C Drug Spending Reached $100M
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
